OX40 Ligand Inhibitors for Moderate-to-Severe Atopic Dermatitis: A Review of Phase II Clinical Trial Data
{{output}}
Atopic dermatitis (AD) is a common, chronic immune-mediated inflammatory skin disease. The OX40-OX40 ligand (OX40L) pathway has emerged as a novel therapeutic target. On this basis, three phase II clinical trials have been conducted to evaluate the efficacy an... ...
